Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303159 · ClinicalTrials.gov registry record · NA
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
A NA study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT01303159 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 29 participants.
The verdict
NCT01303159, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and ability of the endoscopic bipolar radiofrequency ablation (RFA) probe (ENDOHPB) to produce an improvement in the management of cancer of the bile duct or the pancreatic duct. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment. The study will look to see if the ENDOHPB is able to keep the stent open longer and perhaps decrease the number of invasive procedures for occluded (blocked) stents.
Interventions
- DEVICE Endoscopic bipolar radiofrequency probe (ENDOHPB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-01-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01303159
The ClinicalTrials.gov registry entry for NCT01303159 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Endoscopic bipolar radiofrequency probe (ENDOHPB) is the first listed.
NCT01303159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01303159 about?
NCT01303159 is a clinical study titled "Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer". The purpose of this study is to assess safety and ability of the endoscopic bipolar radiofrequency ablation (RFA) probe (ENDOHPB) to produce an improvement in the management of cancer of the bile duct or the pancreatic duct. By using radiofrequency (RF) energy to heat the tissue in the duct prior to...
What is the current status of trial NCT01303159?
This trial is currently terminated. It is a NA study. The enrollment target is 29 participants. The study started on 2010-03. Estimated completion is 2014-01-13.
What interventions are being tested in trial NCT01303159?
The interventions under investigation include: Endoscopic bipolar radiofrequency probe (ENDOHPB) (DEVICE).
Who is sponsoring clinical trial NCT01303159?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.